Nick Shipley, the chief advocacy officer at the Biotechnology Innovation Organization (BIO), has left the trade group, Endpoints News has learned.
Shipley played a key role in Washington lobbying on the biotech industry’s behalf, including a bill that would bar some Chinese life science companies from doing business with US biotechs.
BIO and Shipley confirmed his departure to Endpoints, and as of Wednesday, his photo and details were no longer listed on BIO’s website.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.